Scoria Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 21 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.97 M
- Revenue Growth -33.25%
- Profit Growth -30.34%
- Ebitda 821.13%
- Net Worth 5.69%
- Total Assets -8.06%
About Scoria Pharmaceuticals
Scoria Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 August 2003 and has a history of 21 years and six months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.97 M.
Shashi Dhiman and Surjeet Ray serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239DL2003PTC121713
-
Company No.
121713
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Aug 2003
-
Date of AGM
27 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Scoria Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surjeet Ray
|
Director | 10-Oct-2018 | Current |
|
Shashi Dhiman
|
Director | 31-Oct-2015 | Current |
Financial Performance of Scoria Pharmaceuticals.
Scoria Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 33.25% decrease. The company also saw a substantial fall in profitability, with a 30.34% decrease in profit. The company's net worth moved up by a moderate rise of 5.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Scoria Pharmaceuticals?
In 2021, Scoria Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.97 M
₹0
Charges Breakdown by Lending Institutions
- Punjab National Bank : 0.50 Cr
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jul 2020 | Others | ₹0.97 M | Open |
| 25 Oct 2013 | Punjab National Bank | ₹5.00 M | Open |
How Many Employees Work at Scoria Pharmaceuticals?
Unlock and access historical data on people associated with Scoria Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Scoria Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Scoria Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
